Background {#Sec1}
==========

Cirrhosis of the liver results in various complications and mortality worldwide, but especially in developed regions \[[@CR1]\]. It is the fourth most common cause of death in Europe and leads to more than a million deaths around the globe annually \[[@CR2], [@CR3]\]. The main etiologies of liver cirrhosis in most areas are infection with hepatitis B or C virus and alcohol abuse \[[@CR1]\]. A French screening program estimated prevalence at 0.3%, and European studies found annual incidences of 15.3--132.6 per 100,000 people \[[@CR3]\].

In the United States, annual medical expenditures related to intensive care unit (ICU) admissions are US \$3 billion, with mean charges of US \$116,200 per admission \[[@CR4]\]. Patients in late-stage liver cirrhosis are likely to be admitted to ICUs for critical conditions such as sepsis and renal or respiratory failure \[[@CR4], [@CR5]\]. Though some studies reported improving outcomes in patients with cirrhosis admitted to ICUs \[[@CR6]\], the prognosis remains poor, with mortality rates as high as 45% or even higher \[[@CR7], [@CR8]\].

It is important to identify the risk factors of cirrhosis of the liver and associated adverse outcomes of patients admitted to ICU. Several prognostic scoring systems have been proposed for risk assessment \[[@CR9]--[@CR12]\], such as the Child-Pugh score \[[@CR13]\], the Model for End-stage Liver Disease \[[@CR14]\], the Acute Physiology and Chronic Health Evaluation \[[@CR15]\], and the Sequential Organ Failure Assessment \[[@CR16]\]. Most previous reports only analyzed risk factors that predict outcomes when stratifying cirrhotic patients admitted to ICU, but did not assess the influence of cirrhosis itself on mortality in ICU or one-year survival after discharge.

We conducted a nationwide population-based retrospective cohort study using Taiwan's National Health Insurance Research Database to investigate ICU mortality in patients with and without liver cirrhosis. We also evaluated the impacts of different comorbidities and cirrhosis-related clinical indictors on ICU mortality and on one-year survival in further stratified analyses.

Methods {#Sec2}
=======

Data sources {#Sec3}
------------

We conducted this study using reimbursement claims data from Taiwan's National Health Insurance Program. This program merged former insurance systems in March 1995 and covers more than 99% of Taiwan's 23 million residents. The National Health Research Institutes established a National Health Insurance Research Database (NHIRD) to record all beneficiaries' inpatient and outpatient medical services. This information includes basic patient demographics, physician's primary and secondary disease diagnoses, treatment procedures, prescribed medications and medical expenditures for all health care services. The validity of this database has been favorably evaluated, and research articles based on it have been accepted in prominent scientific journals worldwide \[[@CR17]--[@CR20]\].

Ethics {#Sec4}
------

This study was conducted in accordance with the Helsinki Declaration. To protect personal privacy, the electronic database was decoded with patient identifications scrambled for further academic access for research. According to Taiwan National Health Research Institutes regulations, informed consent is not required because patient identifications were decoded and scrambled \[[@CR18]--[@CR20]\]. Ethical approval for this study (TMU-JIRB-201504008) was provided by the Institutional Review Board of Taipei Medical University.

Study design {#Sec5}
------------

Among 23 million beneficiaries, 1,250,300 patients were admitted to ICU between 2006 and 2012 (Additional file [1](#MOESM1){ref-type="media"}: Figure S1). We identified 79,528 patients aged ≥20 years who had histories of liver cirrhosis from the National Health Insurance Research Database. Patients with liver cirrhosis were defined as having at least two visits for medical care with physician's primary diagnosis of liver cirrhosis within the 24 months before ICU admission. To select appropriate comparison groups, we matched each ICU patient with cirrhosis with one randomly selected ICU patients without liver cirrhosis by the analysis with a propensity score-matched pair procedure (case-control ratio = 1:1). These matched factors included age, sex, low income, stay in medical center or not, diabetes, hypertension, mental disorder, chronic obstructive pulmonary disease, fracture, pneumonia, stroke, asthma, traumatic brain injury, congestive heart failure, immune thrombocytopenia, renal dialysis, hyperlipidemia, epilepsy, atrial fibrillation, peripheral vascular disease and systemic lupus erythematosus, causes of admission to ICU according to physician's primary diagnosis (digestive disease, cancer, respiratory disease, circulatory disease, infectious disease, injury and poisoning, symptom-defined conditions, genitourinary disease, endocrine disease, musculoskeletal disease, neurological disease, skin disease, mental disorder, tumors, blood diseases, congenital anomalies, disease of perinatal period, complications of pregnancy, ICU complications (such as septicemia, pneumonia, acute renal failure, urinary tract infection, stroke, acute myocardial infarction and pulmonary embolism). After matching selection, there were 37,197 patients with cirrhosis of liver in the exposure group and 37,197 people without liver cirrhosis in non-exposure group. We investigated the impact of liver cirrhosis on 30-day mortality, ICU mortality, and one-year mortality among ICU patients in this study.

Measures and definitions {#Sec6}
------------------------

Income status was identified by defining low-income patients as those who qualified for waived medical copayment, as this status is verified by the National Health Insurance Bureau. Whether patients stayed in medical center ICUs or those in other hospitals was also recorded. We used the *International Classification of Diseases, Ninth Revision, Clinical Modification* (ICD-9-CM) to define coexisting medical conditions and ICU complications. Details codes of ICD-9-CM for these diseases were listed in Additional file [1](#MOESM1){ref-type="media"}: Table S1. Cirrhosis of liver before ICU stay was defined as the major exposure. Coexisting medical conditions determined from medical claims within the 24-month period before ICU stay included diabetes, hypertension, mental disorders, chronic obstructive pulmonary disease, fracture, pneumonia, stroke, asthma, traumatic brain injury, congestive heart failure, immune thrombocytopenia, hyperlipidemia, epilepsy, atrial fibrillation, peripheral vascular disease, and systemic lupus erythematosus. Renal dialysis was defined by administration code (D8, D9). Seven major complications during the ICU stay were analyzed (and those having severe cases of these diseases before ICU were excluded) including septicemia, pneumonia, acute renal failure, urinary tract infection, stroke, acute myocardial infarction, and pulmonary embolism. Length of hospital stay and ICU medical expenditure were analyzed as secondary outcomes.

Causes of admission to ICU (according to physician's primary diagnosis at admission) were also identified and described with disease codes including digestive disease, cancer, respiratory disease, circulatory disease, infectious disease, injury and poisoning, symptom-defined conditions, genitourinary disease, endocrine disease, musculoskeletal disease, neurological disease, skin disease, mental disorder, tumor, blood disease, congenital anomalies, disease of perinatal period, and pregnancy complications.

Statistical analysis {#Sec7}
--------------------

To reduce confounding bias, we used a propensity score-matched pair combined with frequency matching procedure to balance the covariates between ICU patients with and without liver cirrhosis. We developed a non-parsimonious multivariable logistic regression model to estimate a propensity score for pre-ICU cirrhosis of the liver. We matched cirrhotic patients to patients without liver cirrhosis, using a greedy matching algorithm (without replacement) with a caliper width of 0.2 SDs of the log odds of the estimated propensity score. Clinical significance guided initial choices of covariates in this multivariable logistic regression model: age, sex, low income, ICU stay in medical center or not, diabetes, hypertension, mental disorders, chronic obstructive pulmonary disease, fracture, pneumonia, stroke, asthma, traumatic brain injury, congestive heart failure, immune thrombocytopenia, renal dialysis, hyperlipidemia, epilepsy, atrial fibrillation, peripheral vascular disease, systemic lupus erythematosus, septicemia, pneumonia, acute renal failure, urinary tract infection, stroke, acute myocardial infarction, pulmonary embolism, digestive disease, cancer, respiratory disease, circulatory disease, infectious disease, injury and poisoning, symptom-defined conditions, genitourinary disease, endocrine disease, musculoskeletal disease, neurological disease, skin disease, mental disorder, tumor, blood disease, congenital anomalies, disease of perinatal period, and complications of pregnancy. A structured iterative approach was used to refine this model to achieve covariate balance within matched pairs. We used chi-square tests to measure covariate balance, and *p* \< 0.05 was suggested to represent meaningful covariate imbalance. We matched patients with and without cirrhosis using a greedy-matching algorithm with a caliper width of 0.2 SD of the log odds of the estimated propensity score. This method could remove 98% of bias from measured covariates.

Adjusted odds ratios (aORs) with 95% confidence intervals (CIs) for 30-day mortality, ICU mortality, and one-year mortality for patients with and without cirrhosis were analyzed with multiple logistic regression models by controlling for age, sex, low income, stay in medical center or not, coexisting medical conditions, ICU complications and admission causes. To confirm associations between liver cirrhosis and ICU mortality, we also performed stratification analysis by age, sex, low income, stay in medical center or not, coexisting medical conditions, ICU complications and causes of ICU admission. The impacts of liver-related indicators and medical care on 30-day mortality in ICU patients with cirrhosis were also measured by calculating adjusted ORs and 95% CIs in the multivariate logistic regression models. SAS version 9.1 (SAS Institute Inc., Cary, NC, USA) statistical software was used for data analyses; two-sided *p* \< 0.05 indicated significant differences.

Results {#Sec8}
=======

The Additional file [1](#MOESM1){ref-type="media"}: Figure S1 shows the flow chart for selecting ICU patients with and without liver cirrhosis. Table [1](#Tab1){ref-type="table"} shows the distributions of age, sex, low income, stay in medical center or not, coexisting medical conditions (diabetes, hypertension, mental disorders, chronic obstructive pulmonary disease, fracture, pneumonia, stroke, asthma, traumatic brain injury, congestive heart failure, idiopathic thrombocytopenic purpura, renal dialysis, hyperlipidemia, epilepsy, atrial fibrillation, peripheral vascular disease, systemic lupus erythematosus), ICU complications (septicemia, pneumonia, acute renal failure, urinary tract infection, stroke, acute myocardial infarction, pulmonary embolism), causes of admission to ICU (digestive disease, cancer, respiratory disease, circulatory disease, infectious disease, injury and poisoning, symptom-defined conditions, genitourinary disease, endocrine disease, musculoskeletal disease, neurological disease, skin disease, mental disorders, tumor, blood disease, congenital anomalies, disease of perinatal period, pregnancy complications) as well as surgery and endotracheal intubation balanced between surgical patients with and without cirrhosis of liver using the matching procedure by propensity score. Table 1Characteristics of ICU patients with and without liver cirrhosisPre-hospital and in-hospital characteristicsNo liver cirrhosis\
(*N* = 37197)Liver cirrhosis\
(*N* = 37197)Age, yearsn(%)n(%) 20--29304(0.8)304(0.8) 30--392261(6.1)2261(6.1) 40--496022(16.2)6022(16.2) 50--598939(24.0)8939(24.0) 60--697832(21.1)7832(21.1) 70--797841(21.1)7841(21.1)  ≥ 803998(10.8)3998(10.8)Sex Female10,274(27.6)10,274(27.6) Male26,923(72.4)26,923(72.4) Low income1192(3.2)1192(3.2) ICU in medical center11,331(30.5)11,331(30.5)Coexisting medical conditions Hypertension8949(24.1)8949(24.1) Diabetes8360(22.5)8360(22.5) Mental disorder6725(18.1)6725(18.1) Peptic ulcer disease6206(16.7)6206(16.7) Anemia4507(12.1)4507(12.1) COPD3561(9.6)3561(9.6) Fracture2495(6.7)2495(6.7) Asthma1250(3.4)1250(3.4) Atherosclerosis1197(3.2)1197(3.2) Traumatic brain injury1063(2.9)1063(2.9) Congestive heart failure832(2.2)832(2.2) Renal dialysis806(2.2)806(2.2) Thrombocytopenia719(1.9)719(1.9)Reasons for ICU admission Digestive disease10,198(27.4)10,198(27.4) Cancer6726(18.1)6726(18.1) Respiratory disease4524(12.2)4524(12.2) Circulatory disease4385(11.8)4385(11.8) Infectious disease3518(9.5)3518(9.5) Injury and poisoning2918(7.8)2918(7.8) Symptom-defined conditions862(2.3)862(2.3) Genitourinary disease762(2.0)762(2.1) Endocrine disease605(1.6)605(1.6) Musculoskeletal disease598(1.6)598(1.6) Mental disorder278(0.8)278(0.8) Neurological disease304(0.8)304(0.8) Skin diseases291(0.8)291(0.8) Tumor254(0.7)254(0.7) Blood disease76(0.2)76(0.2) Congenital anomalies40(0.1)40(0.1) Disease of perinatal period33(0.1)33(0.1) Pregnancy complications7(0.02)7(0.02) Receiving surgery15,297(41.1)15,297(41.1) Endotracheal intubation13,076(35.1)13,076(35.1)Complications in ICU Septicemia7338(19.7)7338(19.7) Pneumonia2970(8.0)2970(8.0) Acute renal failure1708(4.6)1708(4.6) Urinary tract infection1681(4.5)1681(4.5) Stroke1438(3.9)1438(3.9) Acute myocardial infarction403(1.1)403(1.1) Pulmonary embolism22(0.1)22(0.1)*COPD* chronic obstructive pulmonary disease, *ICU* intensive care unit

In Table [2](#Tab2){ref-type="table"}, patients with cirrhosis showed higher ICU medical expenditure than patients without (12,008 ± 9890 vs. 11,366 ± 8742 USD, *p* \< 0.0001). Cirrhosis was associated with a significant increase in 30-day mortality (aOR 1.60, 95% CI 1.53 to 1.68), ICU mortality (aOR 1.44, 95% CI 1.38 to 1.51), and one-year mortality (aOR 1.40, 95% CI 1.35 to 1.46) in ICU patients. Table 2Intensive care unit mortality in patients with and without liver cirrhosisOutcomes of ICUNo LC, %LC, %OR(95% CI)^a^30-day mortality10.915.91.60(1.53 to 1.68)ICU mortality12.917.21.44(1.38 to 1.51)One-year mortality17.322.11.40(1.35 to 1.46)Medical expenditure, USD^b^11,366 ± 874212,008 ± 9890*p* \< 0.0001Length of hospital stay, days^b^8.6 ± 29.68.3 ± 29.2*p* = 0.2174*CI* confidence interval, *ICU* intensive care unit, *OR* odds ratio^a^Adjusted all.covariates listed in Table [1](#Tab1){ref-type="table"}^b^Mean ± SD

Compared with ICU patients without cirrhosis (Table [3](#Tab3){ref-type="table"}), cirrhotic ICU patients had increased 30-day mortality when they also had liver cancer (aOR 1.85, 95% CI 1.74 to 1.97), hepatitis B or C virus infection (aOR 1.75, 95% CI 1.50 to 2.03), alcohol dependence syndrome (aOR 1.82, 95% CI 1.62 to 2.04), jaundice (aOR 2.23, 95% CI 2.03 to 2.45), ascites (aOR 2.32, 95% CI 2.19 to 2.46), gastrointestinal hemorrhage (aOR 1.90, 95% CI 1.78 to 2.03), hepatic coma (aOR 2.21, 95% CI 2.07 to 2.36), more than 4 admissions due to LC (aOR 2.52, 95% CI 2.20 to 2.89), more than 30 days of hospital stay due to LC (aOR 2.97, 95% CI 2.66 to 3.31), and albumin supplement (aOR 1.93, 95% CI 1.83 to 2.04). The aORs of alcohol-related cirrhosis and previous hospitalization associated with 30-day mortality were 1.75 (95% CI 1.66 to 1.85) and 1.52 (95% CI 1.46 to 1.58), respectively. Table 3Stratified analysis and effects of cirrhosis-related clinical indicators on 30-day mortality of ICU patientsn30-day mortalityDeathsMortality, %OR(95% CI)^a^Pre-ICU characteristics within 2 years No LC37,197404610.91.00(reference) LC without liver cancer25,758370514.41.48(1.41 to 1.56) LC with liver cancer11,439219019.21.85(1.74 to 1.97) LC with no HBV and HCV22,258336615.11.55(1.47 to 1.63) LC with HBV or HCV13,573228816.91.67(1.58 to 1.77) LC with HBV and HCV136624117.61.75(1.50 to 2.03) LC without ADS34,496545015.81.59(1.52 to 1.66) LC with ADS270144516.51.82(1.62 to 2.04) LC without jaundice33,978517115.21.54(1.47 to 1.62) LC with jaundice321972422.52.23(2.03 to 2.45) LC without ascites26,352333212.61.30(1.23 to 1.37) LC with ascites10,845256323.62.32(2.19 to 2.46) LC without GI hemorrhage27,652411414.91.50(1.43 to 1.58) LC with GI hemorrhage9545178118.71.90(1.78 to 2.03) LC without hepatic coma29,252410214.01.43(1.37 to 1.37) LC with hepatic coma7945179322.62.21(2.07 to 2.36) LC with 0 admission25,677337813.21.33(1.26 to 1.40) LC with 1 admission6600141121.42.16(2.01 to 2.32) LC with 2 admissions244952121.32.14(1.92 to 2.38) LC with 3 admissions105924823.42.37(2.03 to 2.76) LC with ≥4 admissions141233723.92.52(2.20 to 2.89) LC with 0 days of hospital stay25,677337813.21.33(1.26 to 1.40) LC with 1--9 days of hospital stay514499619.41.92(1.77 to 2.08) LC with 10--19 days of hospital stay302266422.02.23(2.02 to 2.45) LC with 20--29 days of hospital stay131230523.32.30(2.00 to 2.65) LC with ≥30 days of hospital stay204255227.02.97(2.66 to 3.31) LC without albumin supplement23,279314013.51.40(1.33 to 1.47) LC with albumin supplement13,918275519.81.93(1.83 to 2.04) LC without alcohol-related illness24,894358114.41.25(1.20 to 1.31) LC with alcohol-related illness12,303231418.81.75(1.66 to 1.85) LC without hospitalizations721475610.50.91(0.84 to 0.98) LC with hospitalizations29,983513917.11.52(1.46 to 1.58)Reasons for ICU admission Digestive disease, no LC10,1985505.41.00(reference) Digestive disease, LC10,198151114.83.23(2.91 to 3.58) Cancer, no LC6726103115.31.00(reference) Cancer, LC6726115417.21.15(1.05 to 1.27) Respiratory disease, no LC452483718.51.00(reference) Respiratory disease, LC452498621.81.24(1.12 to 1.38) Circulatory disease, no LC43853848.81.00(reference) Circulatory disease, LC438553012.11.47(1.28 to 1.70) Infectious disease, no LC351880722.91.00(reference) Infectious disease, LC351898327.91.32(1.19 to 1.48) Injury and poisoning, no LC29181926.61.00(reference) Injury and poisoning, LC291834511.81.95(1.61 to 2.35) Symptom-defined conditions, no LC86212314.31.00(reference) Symptom-defined conditions, LC86219422.51.86(1.43 to 2.42) Genitourinary disease, no LC762385.01.00(reference) Genitourinary disease, LC762597.71.74(1.10 to 2.75) Endocrine disease, no LC605244.01.00(reference) Endocrine disease, LC605315.11.36(0.76 to 2.43) Musculoskeletal disease, no LC598172.81.00(reference) Musculoskeletal disease, LC598427.03.49(1.79 to 6.82) Mental disorder, no LC27800.01.00(reference) Mental disorder, LC27800.0---- Neurological disease, no LC304113.61.00(reference) Neurological disease, LC304258.22.94(1.30 to 6.65) Skin disease, no LC29172.41.00(reference) Skin disease, LC29182.81.23(0.35 to 4.39) Tumor, no LC25420.81.00(reference) Tumor, LC25452.03.33(0.51 to 21.8) Blood disease, no LC7656.61.00(reference) Blood disease, LC7634.00.38(0.05 to 2.84) Congenital anomalies, no LC4012.51.00(reference) Congenital anomalies, LC4000.0---- Disease of perinatal period, no LC3313.01.00(reference) Disease of perinatal period, LC3300.0---- Complications of pregnancy, no LC700.01.00(reference) Complications of pregnancy, LC7114.3---- 0 CCI score, no LC10,476106610.21.00(reference) 0 CCI score, LC11651018.70.97(0.77 to 1.23) 1 CCI score, no LC88997318.21.00(reference) 1 CCI score, LC665681812.31.38(1.21 to 1.58) 2 CCI score, no LC65735929.01.00(reference) 2 CCI score, LC511659211.61.49(1.31 to 1.70) 3 CCI score, no LC38973559.11.00(reference) 3 CCI score, LC547876013.91.45(1.25 to 1.69) 4 CCI score, no LC182320911.51.00(reference) 4 CCI score, LC7085132518.71.40(1.17 to 1.67)  ≥ 5 CCI score, no LC5529109319.81.00(reference)  ≥ 5 CCI score, LC11,697229919.71.08(0.99 to 1.18)*ADS* alcohol dependence syndrome, *CI* confidence interval, *GI* gastrointestinal, *HBV* hepatitis B virus, *HCV* hepatitis C virus, *ICU* intensive care unit, *LC* liver cirrhosis, *OR* odds ratio^a^Adjusted all covariates listed in Table [1](#Tab1){ref-type="table"}

The association between liver cirrhosis and ICU mortality was significant in relation to the following causes of ICU admission: digestive disease (aOR 3.23, 95% CI 2.91 to 3.58), cancer (aOR 1.15, 95% CI 1.05 to 1.27), respiratory disease (aOR 1.24, 95% CI 1.12 to 1.38), circulatory disease (aOR 1.47, 95% CI 1.28 to 1.70), infectious disease (aOR 1.32, 95% CI 1.19 to 1.48), injury and poisoning (aOR 1.95, 95% CI 1.61 to 2.35), symptom-defined conditions (aOR 1.86, 95% CI 1.43 to 2.42), genitourinary disease (aOR 1.74, 95% CI 1.10 to 2.75), musculoskeletal disease (aOR 3.49, 95% CI 1.79 to 6.82), and neurological disease (aOR 2.94, 95% CI 1.30 to 6.65). The 30-day mortality was also associated with LC in ICU patients with 2 scores (aOR 1.49, 95% CI 1.31 to 1.70), 3 scores (aOR 1.45, 95% CI 1.25 to 1.69), and 4 scores (aOR 1.40, 95% CI 1.17 to 1.67) of Charlson Comorbidity Index.

Stratified analysis and effects of cirrhosis-related clinical indicators on ICU mortality and one-year mortality of ICU patients were showed in Additional file [1](#MOESM1){ref-type="media"}: Tables S2 and S3. The actual survival starting at the day of ICU admission in patients with and without liver cirrhosis was showed in Additional file [1](#MOESM1){ref-type="media"}: Table S4.

Discussion {#Sec9}
==========

In this large-scale, nationwide, population-based propensity score-matched study, patients with cirrhosis of the liver admitted to ICU showed significantly higher ICU mortality as well as increased medical expenditure compared with non-cirrhotic controls. The stratified analyses showed higher ICU mortality among patients with increasing numbers of co-morbidities. Associated with even higher ICU mortality were cirrhosis-related clinical conditions, liver cancer, alcohol dependence syndrome, jaundice, ascites, gastrointestinal hemorrhage and hepatic coma. Regarding long-term outcomes after ICU discharge, higher one-year mortality was noted in liver cirrhosis patients with older age, male gender, ICU in medical center, anemia, renal dialysis, congestive heart failure, and complications in ICU such as septicemia and pneumonia.

To the best of our knowledge, this is the first report investigating the influence of liver cirrhosis on 30-day mortality, ICU mortality, and one-year mortality in ICU patients using a nationwide database. Previous studies were mostly conducted from a single center \[[@CR10], [@CR12], [@CR21]--[@CR24]\], which may represent a certain type of patient group and medical practice. Although these studies evaluated risk factors among patients with liver cirrhosis admitted to ICU, they did not note various cirrhosis-related clinical characteristics nor assess the impact of cirrhosis per se, adjusting all covariates with the control group to the ICU mortality \[[@CR7], [@CR10]--[@CR12], [@CR25], [@CR26]\]. In our subgroup analyses, the odds ratios of ICU mortality in cirrhotic patients' ICU admissions with primary diagnoses such as cancer, respiratory disease and infectious disease were lower than other causes of ICU admission. This might be attributed to cancer, pneumonia, COPD and sepsis having more impact on ICU mortality than cirrhosis after adjustment \[[@CR27]--[@CR29]\].

Regarding the effects of cirrhosis-related clinical indicators on ICU mortality, cirrhotic patients with liver cancer, alcohol dependence syndrome, jaundice, ascites, gastrointestinal hemorrhage and hepatic coma had higher ICU mortality than those without cirrhosis. Of these cirrhosis-related clinical indicators, jaundice, ascites and hepatic coma were consistent with the Child-Pugh score risk factors of the most commonly used prognosis predicting model in cirrhotic patients \[[@CR13]\]. The development of ascites, gastrointestinal hemorrhage, encephalopathy and jaundice mark the decompensated stage of liver cirrhosis that results in poorer prognoses \[[@CR30], [@CR31]\]. These complications might contribute to the increased ICU mortality found in patients of liver cirrhosis with more hospitalization. Liver cancer, especially hepatocellular carcinoma, is one of the leading causes of death in Taiwan \[[@CR32]\], so it is reasonable that cirrhotic patients with liver cancer would have higher ICU mortality than those without it.

Regarding increased ICU mortality and medical expenditures, there are some possible explanations why patients with liver cirrhosis had worse outcomes. First, patients with liver cirrhosis are presumed to have impaired immune function and are thus more susceptible to severe infection, leading to higher mortality \[[@CR33], [@CR34]\]. A previous study demonstrated that infection increased mortality in patients with cirrhosis of liver fourfold, with 30% of patients dying within a month of infection and another 30% dying within a year \[[@CR35]\]. This was consistent with our finding that septicemia and pneumonia in patients with cirrhosis were associated with higher ICU mortality. Second, portal hypertension and subsequent esophageal variceal bleeding and ascites play major roles as complications of cirrhosis and are associated with 1-year mortality of nearly 20% \[[@CR1], [@CR5], [@CR36]\]. Third, as cirrhosis progresses, the development of renal vasoconstriction leads to hepatorenal syndrome. Renal failure is an indicator of end-stage liver disease and increases mortality risk by seven times, with half of patients dying within a month \[[@CR37]\]. In our study, acute renal failure was also significantly associated with ICU mortality. To reduce ICU mortality in patients with liver cirrhosis, health care teams should optimize management of these specific issues according to updated guidelines.

Concerning long-term outcomes, variables such as serum albumin or bilirubin levels, ascites, encephalopathy, and prothrombin time for the Child-Pugh score are the most common independent predictors of mortality in patients with liver cirrhosis \[[@CR5]\]. In our national cohort, ICU mortality among patients with liver cirrhosis increased with numbers of cirrhosis-related clinical conditions. These findings were compatible with previous studies demonstrating high mortality in cirrhotic patients with renal failure and gastrointestinal hemorrhage \[[@CR37], [@CR38]\]. However, our study focused on impacts on long-term mortality after ICU discharge, which was not investigated before. Considering specific management of these factors for ICU patients with cirrhosis of the liver is warranted to reduce mortality.

The present study has strengths of large sample sizes and adjustment for potential confounding factors by propensity score-matching method in a nationwide population-based retrospective cohort. It also has some limitations encountered in research based on secondary data. First, detailed information on laboratory data, physical examinations, and hemodynamic parameters was not available from reimbursement claim data. For example, the international normalized ratio of prothrombin time, bilirubin and creatinine level in blood would help to predict outcomes among cirrhosis patients \[[@CR13], [@CR14]\]. Second, severity of liver cirrhosis noted by Child-Pugh score, Model For End-Stage Liver Disease score or other criteria was not found in reimbursement data for risk stratification of ICU mortality. Third, though the accuracy of major diagnosis codes from the Taiwan National Health Insurance Research Database has been accepted by scientific journals \[[@CR17]--[@CR20]\], the validity of liver cirrhosis, comorbidity and complication codes employed in this study might still be questioned. To reduce the possibility of misdiagnosis or miscoding, we applied inclusive criteria of at least two visits for medical services with physician's primary diagnosis of liver cirrhosis. In addition, an important factor influencing ICU outcome is Do Not Resuscitate orders. However, we have no data regarding the Do Not Resuscitate order in this study because of the limitations of Taiwan's National Health Insurance Research Database. Finally, we could not exclude the possibility that some patients with hepatitis without cirrhosis were included in cirrhotic group in this study because the diagnosis error by physicians may occur in the clinical settings.

Conclusions {#Sec10}
===========

In conclusion, this nationwide population-based study showed that patients with liver cirrhosis admitted to ICU have higher ICU and one-year mortality after discharge in patterns that closely correlate with medical conditions and specific scenarios. These findings can help health care providers develop specific protocols to improve prognosis and long-term survival rates for ICU patients with liver cirrhosis.
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